Maria Karasarides, Ph.D. is a visionary scientist and drug developer with an unwavering commitment to transforming patient care through innovative medicines. Driven by a mission to deliver value to patients and innovation to the marketplace, she is recognized for building high-performance teams, driving impact through real-world problem solving, and igniting collaborations that shape healthcare. In the biopharmaceutical industry, her experience spans 20 years of advancing early and late-stage drug development, translational research, diagnostic biomarkers, and drug commercialization within large organization including Bristol Meyers Squibb, Astra Zeneca and Regeneron. Her career highlights include significant contributions to the development and approval of Yervoy and Imfinzi, and a pipeline of exploratory early-stage clinical immunotherapy combinations. Recognizing the ongoing need for more effective treatments, she is a champion of multi-omic research, AI-based predictive technologies, and integrated precision medicine strategies. She co-founded GUIDE.MRD, a public private partnership that will produce reference standards for benchmarking ctDNA assays and is active in advancing the utility of minimal residual disease (MRD) in solid tumors. She currently serves on the scientific advisory boards of Picture Health, ReviveMed, REVO Oncology, and ViewsML and is a Board Member of FT3, a non-profit organization focused on making precision medicine and biomarker testing accessible to patients, globally.